SEC Comment Letter for RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643) (RLMD) — Dec 3, 2014
RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643)
Date: Dec. 3, 2014 · CIK: 0001553643 · Accession: 0000000000-14-061627
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-197109
Referenced dates: November 3, 2014
Letter
December 2 , 2014 Via E -mail Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 546 Fifth Avenue 14th Floor New York, NY 10036
Re: Relmada Therapeutics, Inc. Amendment No. 3 to Registration Statement on Form S -1 Filed November 17, 2014 File No. 333-197109
Dear Mr. Traversa :
We have reviewed your responses to the comments in our letter dated November 3, 2014 and have the following additional comments.
Management’s Discussion and Analysis, page 61
1. We note your response to our prior comment 6 and reissue in part. Please explain to us the extent to which selling this licensed product is a material part of your business plan. In this regard, we note that this is the only patented product in your port folio. If the agreement is a material part of your business plan , please file the agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S -K or please tell us why you are not required to do so.
Sergio Traversa Relmada Therapeutics, Inc. December 2 , 2014 Page 2
You may contact Aamira Chaudhry (202) 551 -3389 or Amy Geddes at (202) 551 -3304 if you have questions regarding comments on the financial statements and related matters. Please contact Ryan Adams at (202) 551 -3191 or me at (202) 551 -3859 with any other questions.
Sincerely,
/s/ John Dana Brown
Show Raw Text
December 2 , 2014 Via E -mail Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 546 Fifth Avenue 14th Floor New York, NY 10036 Re: Relmada Therapeutics, Inc. Amendment No. 3 to Registration Statement on Form S -1 Filed November 17, 2014 File No. 333-197109 Dear Mr. Traversa : We have reviewed your responses to the comments in our letter dated November 3, 2014 and have the following additional comments. Management’s Discussion and Analysis, page 61 1. We note your response to our prior comment 6 and reissue in part. Please explain to us the extent to which selling this licensed product is a material part of your business plan. In this regard, we note that this is the only patented product in your port folio. If the agreement is a material part of your business plan , please file the agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S -K or please tell us why you are not required to do so. Sergio Traversa Relmada Therapeutics, Inc. December 2 , 2014 Page 2 You may contact Aamira Chaudhry (202) 551 -3389 or Amy Geddes at (202) 551 -3304 if you have questions regarding comments on the financial statements and related matters. Please contact Ryan Adams at (202) 551 -3191 or me at (202) 551 -3859 with any other questions. Sincerely, /s/ John Dana Brown John Dana Brown Attorney Advisor cc: Via-Email Thomas R. Slusarczyk The Matt Law Firm, PLLC